Immune biomarkers of treatment failure for a patient on a phase I clinical trial of pembrolizumab plus radiotherapy

Immune biomarkers of treatment failure for a patient on a phase I clinical trial of pembrolizumab plus radiotherapy

Abstract Background Pembrolizumab is a monoclonal antibody that is designed against programmed cell death protein 1 (PD-1). Pembrolizumab and other immunocheckpoint-blocking monoclonal antibodies work by modulating a patient’s own immune system to increase anti-tumor activity. While immunocheckpoint...

Full description

Bibliographic Details
Main Authors: Gregory S. Alexander, Joshua D. Palmer, Madalina Tuluc, Jianqing Lin, Adam P. Dicker, Voichita Bar-Ad, Larry A Harshyne, Jennifer Louie, Colette M. Shaw, D. Craig Hooper, Bo Lu
Format: Article
Language:English
Published: BMC 2016-09-01
Series:Journal of Hematology & Oncology
Subjects:
Pembrolizumab
Renal cell carcinoma
Radiotherapy
Immunotherapy
Case report
Online Access:http://link.springer.com/article/10.1186/s13045-016-0328-4

Internet

http://link.springer.com/article/10.1186/s13045-016-0328-4

Similar Items